Polycythemia Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

(Albany, USA) DelveInsight's "Polycythemia Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Polycythemia, historical and forecasted epidemiology as well as the Polycythemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Polycythemia market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the Polycythemia market.

To Know in detail about the Polycythemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Market Forecast - https://www.delveinsight.com/report-store/polycythemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Polycythemia Market Report:
• The Polycythemia market size was valued approximately USD 1900 million in the 7MM in the year 2024 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In May 2025, The FDA has granted Fast Track designation to givinostat (Duvyzat) for the treatment of Polycythemia Vera, according to a press release from its developer, Italfarmaco. Previously, givinostat received orphan drug designation for the same indication from both the FDA and the European Medicines Agency (EMA). Additionally, the drug has been approved by the FDA and the UK's Medicines and Healthcare Products Regulatory Agency for the treatment of Duchenne muscular dystrophy.
• In March 2025, Protagonist Therapeutics, Inc. (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline results from the Phase 3 VERIFY study. The trial involved phlebotomy-dependent Polycythemia Vera (PV) patients, who were randomly assigned to receive either rusfertide or a placebo alongside standard care. The study successfully achieved its primary endpoint along with all four key secondary endpoints. Rusfertide, an investigational first-in-class hepcidin mimetic peptide therapeutic, has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA).
• In December 2024, Silence Therapeutics plc ("Silence" or the "Company") (Nasdaq: SLN), a global clinical-stage company focused on developing innovative siRNA (short interfering RNA) therapies, today announced the presentation of additional results from the Phase 1 open-label segment of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with Polycythemia Vera (PV) at the American Society of Hematology (ASH) Annual Meeting.
• In June 2024, AOP Orphan Pharmaceuticals GmbH (AOP Health) continues its successful hematology/oncology clinical research program with two abstracts accepted for presentation at the European Hematology Association (EHA) 2024 hybrid congress in Madrid, Spain. One abstract includes an oral presentation of the latest findings from the PROUD-PV and CONTINUATION-PV trials. The results demonstrate a link between genetic changes (molecular response) and event-free survival (EFS) in Polycythemia Vera (PV) patients treated with ropeginterferon alfa-2b (BESREMi®) or the best available treatment.
• In February 2024, Disc Medicine has disclosed that the US FDA has awarded Orphan Drug Designation to DISC-3405 for treating patients with PV. Additionally, in September 2023, the FDA granted fast track designation to MWTX-003, also known as DISC-3405, for PV treatment.
• In January 2024, Takeda and Protagonist Therapeutics have established a global licensing and collaboration agreement for rusfertide.
• In 2023, the United States had the highest number of cases among the 7MM. The total number of prevalent PV cases in the US in 2023 was approximately 180,000.
• In the EU4 and the UK, Germany had the highest number of PV cases, with nearly 25,000 cases in 2023, whereas Spain reported the lowest number of cases in the same year.
• As per Orphanet, PV affects 30 out of every 100,000 individuals in Germany. When extrapolated to the entire population, this translates to approximately 24,000 affected people.
• According to Kuykendall (2023), as many as 25% of patients develop resistance to or cannot tolerate hydroxyurea.
• Key Polycythemia Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
• Key Polycythemia Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
• The Polycythemia epidemiology based on gender analyzed that mostly males are affected in case of Polycythemia
• The Polycythemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polycythemia pipeline products will significantly revolutionize the Polycythemia market dynamics.

Polycythemia Overview
Polycythemia is a rare blood disorder characterized by an increased number of red blood cells, leading to thicker blood and reduced blood flow. Polycythemia Vera (PV) is the most common type, classified as a myeloproliferative neoplasm and often associated with the polycythemia JAK2 mutation, which plays a crucial role in disease development. Polycythemia symptoms typically include headache, dizziness, fatigue, itching (especially after a hot shower), and a ruddy complexion. In more severe cases, polycythemia complications can include blood clots, strokes, and heart attacks due to increased blood viscosity.
Polycythemia diagnosis involves blood tests to check hematocrit and hemoglobin levels, along with genetic testing for the polycythemia JAK2 V617F mutation. Polycythemia treatment aims to reduce red blood cell count and prevent complications through phlebotomy, low-dose aspirin, and in some cases, cytoreductive therapy such as hydroxyurea. Emerging therapies are focusing on targeting the molecular pathways of Polycythemia disease progression.
Raising awareness of polycythemia early detection and ensuring proper polycythemia management are essential for improving patient outcomes. As research continues to evolve, new polycythemia clinical trials and treatments offer hope for those living with this chronic condition. Regular monitoring and individualized care are key to effective polycythemia prognosis.

Get a Free sample for the Polycythemia Market Report: https://www.delveinsight.com/sample-request/polycythemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Polycythemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polycythemia Epidemiology Segmentation:
The Polycythemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Polycythemia
• Prevalent Cases of Polycythemia by severity
• Gender-specific Prevalence of Polycythemia
• Diagnosed Cases of Episodic and Chronic Polycythemia

Download the report to understand which factors are driving Polycythemia epidemiology trends @ Polycythemia Epidemiology Forecast - https://www.delveinsight.com/report-store/polycythemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Polycythemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia market or expected to get launched during the study period. The analysis covers Polycythemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Polycythemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polycythemia Therapies and Key Companies
• Rusfertide (PTG-300): Protagonist Therapeutics
• Givinostat (ITF2357): Italfarmaco
• Bomedemstat: Imago BioSciences
• SLN124: Silence Therapeutics
• Sapablursen: Ionis Pharmaceutical
• PPMX-T003: Perseus Proteomics
• PTG-300: Protagonist Therapeutics, Inc.
• SLN124: Silence Therapeutics plc
• Hydroxyurea: Novartis
• Ropeginterferon alfa-2b: PharmaEssentia
• PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
• Ruxolitinib: Incyte Corporation

Discover more about therapies set to grab major Polycythemia market share @ Polycythemia Treatment Market - https://www.delveinsight.com/sample-request/polycythemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Polycythemia Market Strengths
• The approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner a big market size in Polycythemia.
• Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients.

Polycythemia Market Opportunities
• An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.
• Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.

Scope of the Polycythemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Polycythemia Companies: Protagonist Therapeutics, Inc. (NASDAQ: PTGX), Italfarmaco, Imago BioSciences (formerly NASDAQ: IMGO, acquired by Merck), Silence Therapeutics (NASDAQ: SLN), Ionis Pharmaceuticals (NASDAQ: IONS), Perseus Proteomics (Tokyo Stock Exchange: 4882), Novartis (SWX: NOVN), PharmaEssentia (Taipei Exchange: 6446), AOP Orphan Pharmaceuticals AG, Incyte Corporation (NASDAQ: INCY), and others
• Key Polycythemia Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
• Polycythemia Therapeutic Assessment: Polycythemia current marketed and Polycythemia emerging therapies
• Polycythemia Market Dynamics: Polycythemia market drivers and Polycythemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Polycythemia Unmet Needs, KOL's views, Analyst's views, Polycythemia Market Access and Reimbursement

To know more about Polycythemia companies working in the treatment market, visit @ Polycythemia Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/polycythemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Polycythemia Market Report Introduction
2. Executive Summary for Polycythemia
3. SWOT analysis of Polycythemia
4. Polycythemia Patient Share (%) Overview at a Glance
5. Polycythemia Market Overview at a Glance
6. Polycythemia Disease Background and Overview
7. Polycythemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Polycythemia
9. Polycythemia Current Treatment and Medical Practices
10. Polycythemia Unmet Needs
11. Polycythemia Emerging Therapies
12. Polycythemia Market Outlook
13. Country-Wise Polycythemia Market Analysis (2020-2034)
14. Polycythemia Market Access and Reimbursement of Therapies
15. Polycythemia Market Drivers
16. Polycythemia Market Barriers
17. Polycythemia Appendix
18. Polycythemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/chronic-pain-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Adamantinoma Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Healthcare Subscription Models: https://www.delveinsight.com/blog/subscription-model-in-healthcare
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Wound Irrigation Systems Market: https://www.delveinsight.com/report-store/wound-irrigation-systems-market?utm_source=Medgadget&utm_medium=pressrelease&utm_campaign=kupr
• Pulse Oximeter Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Menopause Market: https://www.delveinsight.com/report-store/menopause-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market
• Aortic Aneurysm Stent Grafts Market: https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Pressure Ulcers Market: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Diabetic Foot Ulcers Dfus Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Vertigo Market: https://www.delveinsight.com/report-store/vertigo-market
• Chronic Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Palmar Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Acute Pain Market: https://www.delveinsight.com/report-store/acute-pain-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/external-defibrillators-market
• Dysthymia Market: https://www.delveinsight.com/report-store/persistent-depressive-disorder-market?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr
• Interbody Cages Market: https://www.delveinsight.com/report-store/interbody-cages-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/knee-osteoarthritis-market
• Palmar Hyperhidrosis Market Size: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market
• X Linked Hypophosphatemia Market: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
• Absssi Market Size: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-syndrome-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Cough Assisted Device Market: https://www.delveinsight.com/report-store/cough-assist-devices-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/blog/duchenne-muscular-dystrophy-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.